Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F, et al. Multiple sclerosis. Lancet. 2024;403(10422):183–202. https://doi.org/10.1016/S0140-6736(23)01473-3.
McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765–79. https://doi.org/10.1001/jama.2020.26858. PMID: 33620411.
GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024 Mar 5:S1474–4422(24)00038–3. https://doi.org/10.1016/S1474-4422(24)00038-3. PMID: 38493795.
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9.
Multiple sclerosis in adults: management (NICE Guideline, No. 220). London: National Institute for Health and Care Excellence (NICE); 2022. Available at: https://www.nice.org.uk/guidance/ng220 (accessed March 19, 2024).
Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–88. https://doi.org/10.1212/WNL.0000000000005347. PMID: 29686116.
Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96–120. https://doi.org/10.1177/1352458517751049. PMID: 29353550.
World Health Organization. WHO endorses landmark public health decisions on essential medicines for multiple sclerosis. Available at: https://www.who.int/news/item/26-07-2023-who-endorses-landmark-public-health-decisions-on-essential-medicines-for-multiple-sclerosis (accessed March 19, 2024).
Laurson-Doube J, Helme A, Nonino F, Piggott T, Rijke N, Saylor D. WHO considers multiple sclerosis treatments essential. Lancet Neurol. 2024;23(2):140. https://doi.org/10.1016/S1474-4422(23)00505-7.
Sumelahti ML, Pukkala E, Hakama M. Cancer incidence in multiple sclerosis: a 35-year follow-up. Neuroepidemiology. 2004;23(5):224–7. https://doi.org/10.1159/000079947. PMID: 15316248.
Achiron A, Barak Y, Gail M, Mandel M, Pee D, Ayyagari R, Rotstein Z. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat. 2005;89(3):265–70. https://doi.org/10.1007/s10549-004-2229-4. PMID: 15754125.
Nielsen NM, Rostgaard K, Rasmussen S, Koch-Henriksen N, Storm HH, Melbye M, et al. Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer. 2006;118(4):979–84. https://doi.org/10.1002/ijc.21437. PMID: 16152598.
Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T. Cancer risk among patients with multiple sclerosis and their parents. Neurology. 2009;72(13):1170–7. https://doi.org/10.1212/01.wnl.0000345366.10455.62. PMID: 19332695.
Kingwell E, Bajdik C, Phillips N, Zhu F, Oger J, Hashimoto S, Tremlett H. Cancer risk in multiple sclerosis: findings from British Columbia. Canada Brain. 2012;135(Pt 10):2973–9. https://doi.org/10.1093/brain/aws148. PMID: 22730559.
Handel AE, Ramagopalan SV. Multiple sclerosis and risk of cancer: a meta-analysis. J Neurol Neurosurg Psychiatry. 2010;81(12):1413–4. https://doi.org/10.1136/jnnp.2009.195776. PMID: 20724517.
Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Sorensen PS, Reingold SC, Cutter G. A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Mult Scler. 2015;21(3):294–304. https://doi.org/10.1177/1352458514564489. PMID: 25533302.
Catalá-López F, Suárez-Pinilla M, Suárez-Pinilla P, Valderas JM, Gómez-Beneyto M, Martinez S, et al. Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies. Psychother Psychosom. 2014;83(2):89–105. https://doi.org/10.1159/000356498. PMID: 24458030.
Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology. 1996;46(6):1607–12. https://doi.org/10.1212/wnl.46.6.1607. PMID: 8649558.
Lebrun C, Debouverie M, Vermersch P, Clavelou P, Rumbach L, de Seze J, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler. 2008;14(3):399–405. https://doi.org/10.1177/1352458507083625. PMID: 18420778.
Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol. 2020;87(5):688–99. https://doi.org/10.1002/ana.25701. PMID: 32056253.
La Mantia L, Benedetti MD, Sant M, d’Arma A, Di Tella S, Lillini R, et al. Cancer risk for multiple sclerosis patients treated with azathioprine and disease-modifying therapies: an Italian observational study. Neurol Sci. 2021;42(12):5157–63. https://doi.org/10.1007/s10072-021-05216-z. PMID: 33791892.
Greenfield J, Metz LM, Khakban A, Llorian ER, Michaux KD, Traboulsee A, et al. Cancer risk, disease-modifying therapy, and age in multiple sclerosis: a retrospective population-based cohort study. Mult Scler Relat Disord. 2023;80 PMID: 37924714.
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm. 2015;2(6) PMID: 26468472.
Papadopoulos D, Gklinos P, Psarros G, Drellia K, Delicha EM, Friede T, et al. Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression. J Neurol. 2022;269(6):3226–37. https://doi.org/10.1007/s00415-021-10932-9. PMID: 35066607.
Tramacere I, Virgili G, Perduca V, Lucenteforte E, Benedetti MD, Capobussi M, et al. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2023;11(11):CD012186. https://doi.org/10.1002/14651858.CD012186.pub2. PMID: 38032059.
Lebrun C, Rocher F. Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs. CNS Drugs. 2018;32(10):939–49. https://doi.org/10.1007/s40263-018-0564-y. PMID: 30143945.
Mavenclad (cladribine). European public assessment report (EPAR). Last updated: 23/01/2024. Amsterdam: European Medicines Agency (EMA); 2024. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad (accessed March 19, 2024).
Gilenya (fingolimod). European public assessment report (EPAR). Last updated: 15/09/2023. Amsterdam: European Medicines Agency (EMA); 2023. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya (accessed March 19, 2024).
Tysabri (natalizumab). European public assessment report (EPAR). Last updated: 21/02/2024. Amsterdam: European Medicines Agency (EMA); 2024. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri (accessed March 19, 2024).
Lemtrada (alentuzumab). European public assessment report (EPAR). Last updated: 05/01/2024. Amsterdam: European Medicines Agency (EMA); 2024. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada (accessed March 19, 2024)
Ocrevus (ocrelizumab). European public assessment report (EPAR). Last updated: 13/04/2023. Amsterdam: European Medicines Agency (EMA); 2023. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus (accessed March 19, 2024)
Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation – have anti-inflammatory therapies come of age? Nat Rev Clin Oncol. 2021;18(5):261–79. https://doi.org/10.1038/s41571-020-00459-9. PMID: 33469195.
Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5):501–7. https://doi.org/10.1016/S1470-2045(09)70035-X. PMID: 19410194.
Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JFF, Roncaglioni MC, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018;392(10145):387–99. https://doi.org/10.1016/S0140-6736(18)31133-4. PMID: 30017552.
Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41. https://doi.org/10.1016/S0140-6736(10)62110-1. PMID: 21144578.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. https://doi.org/10.1186/2046-4053-4-1.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350: g7647. https://doi.org/10.1136/bmj.g7647.
Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352: i157. https://doi.org/10.1136/bmj.i157.
McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40–6. https://doi.org/10.1016/j.jclinepi.2016.01.021.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available at: www.training.cochrane.org/handbook (accessed March 19, 2024)
Glanville J, Foxlee R, Wisniewski S, Noel-Storr A, Edwards M, Dooley G. Translating the Cochrane EMBASE RCT filter from the Ovid interface to Embase.com: a case study. Health Info Libr J. 2019;36(3):264–277. https://doi.org/10.1111/hir.12269. PMID: 31328866.
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https://doi.org/10.1186/s13643-016-0384-4.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366 PMID: 31462531.
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2008. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed March 19, 2024)
Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335–71. https://doi.org/10.1016/s0033-0620(85)80003-7. PMID: 2858114.
Bradburn MJ, Deeks JJ, Berlin JA, Russell LA. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26(1):53–77. https://doi.org/10.1002/sim.2528.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. https://doi.org/10.1016/0197-2456(86)90046-2. PMID: 3802833.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557.
Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29. https://doi.org/10.2307/3001666.
Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Elie A Akl EA, Nicole Skoetz N, et al. Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane Collaboration, 2024. Available from: https://training.cochrane.org/handbook/current/chapter-14
Santesso N, Carrasco-Labra A, Langendam M, Brignardello-Petersen R, Mustafa RA, Heus P, et al. Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments. J Clin Epidemiol. 2016;74:28–39. https://doi.org/10.1016/j.jclinepi.2015.12.006. PMID: 26796947.
Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2020;119:126–35. https://doi.org/10.1016/j.jclinepi.2019.10.014. PMID: 31711912.
Harbord RM, Higgins JPT. Meta-regression in Stata. Stata J. 2008;8(4):493–519.
White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014;46(3 Suppl 1):S7-15. https://doi.org/10.1016/j.amepre.2013.10.029. PMID: 24512933.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629. PMID: 9310563.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994D;50(4):1088–101. https://doi.org/10.2307/2533446. PMID: 7786990.
StataCorp: Stata Statistical Software: Release 18. College Station, TX: StataCorp LP; 2023.
Palmer TM, Sterne JAC, Newton HJ, Cox NJ, editors. Meta-analysis in Stata: an updated collection from the Stata journal. 2nd ed. College Station, TX: StataCorp LP; 2016.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, Del Giovane C, Peryer G, Piggott T, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2024;1(1):CD011381. https://doi.org/10.1002/14651858.CD011381.pub3. PMID: 38174776.
Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, et al. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Cochrane Database Syst Rev. 2017;4(4):CD012200. https://doi.org/10.1002/14651858.CD012200.pub2. PMID: 28440858.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. https://doi.org/10.1186/s13643-021-01626-4.PMID:33781348;PMCID:PMC8008539.
Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372 PMID: 33781993.
Add Comment